Literature DB >> 466860

Antibody-dependent and phytohaemagglutinin-induced lymphocyte cytotoxicity in systemic sclerosis.

J K Wright, P Hughes, N R Rowell, I B Sneddon.   

Abstract

Cell-mediated cytotoxicity was examined in thirty-seven patients with systemic sclerosis using both whole blood and purified peripheral blood mononuclear cells (PBM) to measure antibody-dependent (ADCC) and phytohaemagglutinin (PHA) induced lymphocyte cytotoxicity to 51Cr-labelled Chang liver cells. In twenty-three mildly affected patients, ADCC and PHA-induced cytotoxicity did not differ from that found in control populations. By contrast, fourteen patients severely affected by extensive visceral disease showed reductions in both ADCC and PHA-induced cytotoxicity which were more marked in whole blood assays (P less than 0.001) than in those performed with PBM (P less than 0.05). The addition of patient's sera to control cytotoxicity assays suggested that blocking or suppressive serum factors could only account for some of the disproportionate reduction in whole blood cytotoxicity which, in the main, must be due to a lack of circulating effector cells. These results are in agreement with previous findings of reduced numbers of circulating thymus-dependent lymphocytes in patients with severe disease, a defect of cell-mediated immunity that may result from the chronic antigenic stimulation of an autoimmune disease process.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 466860      PMCID: PMC1537708     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  19 in total

1.  Thymus-dependent (T) lymphocyte deficiency in progressive systemic sclerosis.

Authors:  P Hughes; S Holt; N R Rowell; J Dodd
Journal:  Br J Dermatol       Date:  1976-11       Impact factor: 9.302

2.  ANTINUCLEAR AND PRECIPITATING AUTOANTIBODIES IN PROGRESSIVE SYSTEMIC SCLEROSIS.

Authors:  J S BECK; J R ANDERSON; K G GRAY; N R ROWELL
Journal:  Lancet       Date:  1963-12-07       Impact factor: 79.321

3.  Scleroderma and its relationship to the "collagenoses": dermatomyositis, lupus erythematosus, rheumatoid arthritis and Sjogren's syndrome.

Authors:  D L TUFFANELLI
Journal:  Am J Med Sci       Date:  1962-02       Impact factor: 2.378

4.  Sjogren's syndrome in association with scleroderma.

Authors:  M A SHEARN
Journal:  Ann Intern Med       Date:  1960-06       Impact factor: 25.391

5.  Sjögren-type syndrome after allogeneic bone-marrow transplantation.

Authors:  A A Gratwohl; A A Gratwhol; H M Moutsopoulos; T M Chused; M Akizuki; R O Wolf; J B Sweet; A B Deisseroth
Journal:  Ann Intern Med       Date:  1977-12       Impact factor: 25.391

6.  The relationship of defective cell-mediated immunity to visceral disease in systemic sclerosis.

Authors:  P Hughes; S Holt; N R Rowell; I D Allonby; K Janis; J K Dodd
Journal:  Clin Exp Immunol       Date:  1977-05       Impact factor: 4.330

7.  Ecotaxis: the principle and its application to the study of Hodgkin's disease.

Authors:  M D Sousa; M Yang; E Lopes-Corrales; C Tan; J A Hansen; B Dupont; R A Good
Journal:  Clin Exp Immunol       Date:  1977-01       Impact factor: 4.330

8.  Localized scleroderma-like lesions after bone marrow transplantation in man. A chronic graft versus host reaction.

Authors:  W A Van Vloten; E Scheffer; L J Dooren
Journal:  Br J Dermatol       Date:  1977-04       Impact factor: 9.302

9.  Sclerodermatous graft-versus-host disease limited to an area of measles exanthem.

Authors:  J R Fenyk; C M Smith; P I Warkentin; W Krivit; R W Goltz; J E Neely; M E Nesbit; N K Ramsay; P F Coccia; J H Kersey
Journal:  Lancet       Date:  1978-03-04       Impact factor: 79.321

10.  HOMOLOGOUS DISEASE IN THE ADULT RAT, A MODEL FOR AUTOIMMUNE DISEASE. I. GENERAL FEATURES AND CUTANEOUS LESIONS.

Authors:  P STASTNY; V A STEMBRIDGE; M ZIFF
Journal:  J Exp Med       Date:  1963-10-01       Impact factor: 14.307

View more
  5 in total

1.  Impaired primary in-vitro antibody response in progressive systemic sclerosis patients: rôle of suppressor monocytes.

Authors:  P Segond; D Salliere; P Galanaud; R M Desmottes; P Massias; J N Fiessinger
Journal:  Clin Exp Immunol       Date:  1982-01       Impact factor: 4.330

2.  Defective Epstein-Barr virus specific suppressor T cell function in progressive systemic sclerosis.

Authors:  A Kahan; A Kahan; C J Menkes; B Amor
Journal:  Ann Rheum Dis       Date:  1986-07       Impact factor: 19.103

3.  Antibody-dependent and phytohaemagglutinin-induced lymphocyte cytotoxicity in systemic lupus erythematosus.

Authors:  J K Wright; P Hughes; K Gelsthorpe; A M Ward; N R Rowell
Journal:  Ann Rheum Dis       Date:  1981-02       Impact factor: 19.103

4.  Lymphocyte cytotoxicity in systemic sclerosis: no increase on short-term culture with established human cell lines.

Authors:  J K Wright; P Hughes; N R Rowell
Journal:  Ann Rheum Dis       Date:  1982-08       Impact factor: 19.103

5.  Spontaneous lymphocyte-mediated (NK cell) cytotoxicity in systemic sclerosis: a comparison with antibody-dependent lymphocyte (K cell) cytotoxicity.

Authors:  J K Wright; P Hughes; N R Rowell
Journal:  Ann Rheum Dis       Date:  1982-08       Impact factor: 19.103

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.